|
Carcinogenesis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The role of antioxidant enzyme peroxiredoxin 2 (PRDX2) in gastric tumorigenesis remains unknown.
|
31536951 |
2020 |
|
Malignant neoplasm of stomach
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the future development of therapeutic approaches targeting PRDX2 may be useful in the treatment of gastric cancer.
|
31536951 |
2020 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the future development of therapeutic approaches targeting PRDX2 may be useful in the treatment of gastric cancer.
|
31536951 |
2020 |
|
Disorder of tendon
|
0.040 |
Biomarker
|
group |
BEFREE |
In conclusion, intra-tendon delivery of Lr-PRP at early stage showed beneficial effect for repair of tendinopathy, but not at late stage.
|
31840415 |
2020 |
|
Tendinopathy
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, intra-tendon delivery of Lr-PRP at early stage showed beneficial effect for repair of tendinopathy, but not at late stage.
|
31840415 |
2020 |
|
Merkel cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Torin-1 treatment induced cell death, which was attenuated by autophagy inhibitor, but not pan-caspase inhibitor, suggesting a potential role of autophagy in promoting cell death in MCC.
|
31180579 |
2020 |
|
Synovitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A clinical, non-randomized, open label comparison of ACS vs PRP in knee OA with sub-clinical or moderate synovitis symptomology was performed.
|
31847701 |
2020 |
|
Postoperative atelectasis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Meta-analysis using a random-effects model showed a decrease in postoperative atelectasis (relative risk [RR], 0.51; 95% confidence interval [CI], 0.35-0.76; trial sequential analyses [TSA]-adjusted CI, 0.10-2.55) and postoperative pneumonia (RR, 0.48; 95% CI, 0.27-0.84; TSA-adjusted CI, 0.05-4.86) in patients receiving PEEP ventilation.
|
31567322 |
2020 |
|
Postoperative pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Meta-analysis using a random-effects model showed a decrease in postoperative atelectasis (relative risk [RR], 0.51; 95% confidence interval [CI], 0.35-0.76; trial sequential analyses [TSA]-adjusted CI, 0.10-2.55) and postoperative pneumonia (RR, 0.48; 95% CI, 0.27-0.84; TSA-adjusted CI, 0.05-4.86) in patients receiving PEEP ventilation.
|
31567322 |
2020 |
|
Liver carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The expression of PRDX2 at both mRNA and protein levels was examined by q‑RT‑PCR, western blotting and immunohistochemical assessment in HCC tissues and cell line HCCLM3.
|
30747220 |
2019 |
|
Liver carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the link between Prx2 and CSC stemness through regulation of ROS levels in hepatocellular carcinoma (HCC) cells.
|
30611866 |
2019 |
|
Esophageal Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines.
|
31804468 |
2019 |
|
Malignant neoplasm of esophagus
|
0.330 |
Biomarker
|
disease |
BEFREE |
The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines.
|
31804468 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silencing of PRDX2 in the HCC cell line HCCLM3 promoted cancer cell proliferation and migration.
|
30747220 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prx2 links ROS homeostasis to stemness of cancer stem cells.
|
30611866 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To further investigate the role of PRP‑1 in chondrosarcoma cells, its effects on cancer stem cell (CSC) populations were determined by analyzing aldehyde dehydrogenase (ALDH) activity, an established marker of CSCs, in association with regulation of the Wnt/β‑catenin signaling.
|
31180539 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Screening of potential biomarkers was performed with 52, and five differentially abundant proteins, peroxiredoxin 2 (PRDX2), thioredoxin (TXN), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), extracellular matrix protein 1 (ECM1), and protein S100 A8 (S100A8), were chosen to undergo validation, for their previously known connection with oxidative stress or cancer.
|
31567534 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, Prx1 and Prx2 are able to bind to a diversity of interaction partners to regulate other various cellular processes in cancer (i.e., regulation of the protein redox status, cell growth, apoptosis, and tumorigenesis).
|
31185618 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peroxiredoxin 2 (Prx2) is a redox regulatory protein that plays a key role in maintaining ROS homeostasis in the tumor microenvironment.
|
30611866 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We pharmacologically knock down HDAC activity using two different inhibitors (TSA and SAHA) in two different tumor cell types: a commercial GBM cell line (U87-MG) and primary tumor (GBM011).
|
31531023 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Prx2 links ROS homeostasis to stemness of cancer stem cells.
|
30611866 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Silencing of PRDX2 in the HCC cell line HCCLM3 promoted cancer cell proliferation and migration.
|
30747220 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, Prx1 and Prx2 are able to bind to a diversity of interaction partners to regulate other various cellular processes in cancer (i.e., regulation of the protein redox status, cell growth, apoptosis, and tumorigenesis).
|
31185618 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Screening of potential biomarkers was performed with 52, and five differentially abundant proteins, peroxiredoxin 2 (PRDX2), thioredoxin (TXN), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), extracellular matrix protein 1 (ECM1), and protein S100 A8 (S100A8), were chosen to undergo validation, for their previously known connection with oxidative stress or cancer.
|
31567534 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
To further investigate the role of PRP‑1 in chondrosarcoma cells, its effects on cancer stem cell (CSC) populations were determined by analyzing aldehyde dehydrogenase (ALDH) activity, an established marker of CSCs, in association with regulation of the Wnt/β‑catenin signaling.
|
31180539 |
2019 |